Retatrutide: the next generation of GLP-1 weight loss medication.
The investigational triple-agonist GLP-1/GIP/glucagon medication from Eli Lilly. Phase 2 data showed 24.2% mean weight loss at 48 weeks. Currently in Phase 3 trials.
The next generation of GLP-1 weight loss medication — in clinical trials, not yet approved.
Retatrutide is Eli Lilly’s investigational triple-agonist medication that activates three receptors at once: GLP-1, GIP, and glucagon. Tirzepatide (currently FDA-approved as Mounjaro and Zepbound) is a dual-agonist hitting GLP-1 and GIP. Retatrutide adds glucagon receptor activity, which appears to drive additional metabolic effects beyond what tirzepatide produces alone.
The Phase 2 trial published in the New England Journal of Medicine in 2023 produced some of the most impressive weight loss data ever recorded for a single medication: 24.2% mean body weight reduction at 48 weeks at the highest dose, compared to about 21% for tirzepatide at similar timepoints. For context, that’s the difference between losing 50 pounds and losing 60 pounds for a 250-pound person — meaningful at a population level.
We don’t prescribe research-grade peptides obtained outside the FDA pathway. What we do offer is the medication that’s actually FDA-approved today, with results approaching what retatrutide delivered in Phase 2 — tirzepatide — and a clinical program that takes the same evidence-first approach we’d take with retatrutide once it’s approved.
Retatrutide vs. tirzepatide vs. semaglutide.
How the three medications compare on weight loss, mechanism, and availability. The pattern is clear: each new generation builds on the last.
FDA-approved · Single agonist
The original FDA-approved GLP-1 for weight loss (Wegovy). Mean weight loss in clinical trials of approximately 15-16% over 68 weeks at the 2.4 mg dose. Activates GLP-1 receptors. Available now, well-tolerated, extensively studied.
Status: FDA-approved · Available · See our semaglutide pageFDA-approved · Dual agonist
The next-generation FDA-approved medication. Mean weight loss of approximately 21-22% over 72 weeks at the 15 mg dose (SURMOUNT-1 trial). Activates GLP-1 and GIP receptors simultaneously. Currently the most effective FDA-approved weight loss medication. Available now under brand names Mounjaro (diabetes) and Zepbound (weight loss).
Status: FDA-approved · Available · See our tirzepatide pageInvestigational · Triple agonist
The next medication in development. Phase 2 trial showed mean weight loss of 24.2% at 48 weeks at the 12 mg dose. Activates GLP-1, GIP, and glucagon receptors. Currently in Phase 3 trials (TRIUMPH program). FDA approval expected 2026 or later. Not yet available through legitimate clinical channels.
Status: Phase 3 trials · Not yet approved · Not currently prescribedIf you’re researching retatrutide, here’s what we can actually do for you now.
The FDA-approved medications available today produce results that are remarkably close to retatrutide’s Phase 2 data. The Tide’s metabolic health program uses these medications with the same rigorous clinical approach we’d take with retatrutide once it’s approved.
Tirzepatide delivers 21-22% mean weight loss. Available, FDA-approved, monitored.
The gap between tirzepatide and retatrutide on weight loss is meaningful but not enormous. Starting today with tirzepatide is the right move for most patients seeking the strongest available metabolic intervention.
- Tirzepatide — FDA-approved, 21-22% mean weight loss in trials, dual GLP-1/GIP agonist
- Semaglutide — FDA-approved, 15-16% mean weight loss, well-established protocol
- Comprehensive metabolic workup — labs, cardiovascular screening, baseline body composition
- Structured titration to therapeutic dose with side effect management
What our metabolic health program looks like today.
Whether you eventually move to retatrutide when it’s approved or stay on tirzepatide, the foundation is the same: real workup, proper titration, ongoing monitoring, and addressing the broader picture.
Initial consultation
In person at our Houston clinic. We discuss your goals, weight loss history, current medications, and what you’ve already tried. We talk through the FDA-approved options (tirzepatide and semaglutide) and our position on retatrutide — we monitor the trial data and will offer it through legitimate channels once approved.
Comprehensive workup
Complete metabolic panel at LabCorp or Quest — A1c, fasting glucose, insulin, lipid panel, complete metabolic panel, liver enzymes, thyroid, vitamin D, and other markers based on your situation. Baseline body composition measurement. Cardiovascular review. We’re establishing the full picture, not just confirming your weight.
Protocol design
Your physician recommends tirzepatide or semaglutide based on your specific situation, goals, and budget. We discuss starting dose, titration schedule, expected timeline for noticeable changes, and side effect management. For patients also dealing with insulin resistance or metabolic syndrome, we discuss how the medication fits with broader metabolic work.
First prescription
FDA-approved brand-name medication (Zepbound, Wegovy, Mounjaro, Ozempic) or compounded version through licensed pharmacies, depending on insurance and cost considerations. Clear instructions on dosing, injection technique, side effect management, and what to expect during titration.
Structured monitoring
Regular check-ins to assess weight loss, side effects, and tolerability. Dose adjustments based on response. Repeat labs at 3 months. If retatrutide becomes available during your treatment course, we discuss whether transitioning makes sense for your specific situation.
Ready to start today with what’s available?
Retatrutide is coming. Tirzepatide and semaglutide are here now — with results approaching what retatrutide showed in Phase 2 trials. A 45-minute consultation with one of our Houston physicians is the right first step.
Why we don’t prescribe retatrutide yet.
We monitor the Phase 3 data closely and will offer retatrutide through legitimate channels when FDA-approved. Here’s what’s behind that position.
What we’ll do when retatrutide is approved
- Add it to our prescribing toolkit through FDA-approved channels
- Discuss it as a primary option for new metabolic health patients alongside tirzepatide and semaglutide
- Help existing tirzepatide patients evaluate whether transitioning makes sense
- Take the same evidence-first approach we take with every medication — proper workup, structured titration, monitoring, and honest assessment of fit
- Update this page as Phase 3 data publishes and the FDA decision approaches
What we won’t do
- Prescribe research-grade peptides obtained outside the FDA-approved supply chain
- Pretend the clinical, regulatory, and safety differences between approved medications and research-grade aren’t meaningful
- Source medications from gray-market suppliers, even when patients request it
- Recommend you do that elsewhere — the safety and quality risks are real
- Use marketing language that obscures the regulatory status
Before you book.
When will retatrutide be FDA-approved?
The Phase 3 TRIUMPH program is ongoing. Eli Lilly has indicated FDA submission likely in 2026, with potential approval in 2026 or 2027 depending on review timelines. The exact timing isn’t certain — Phase 3 results need to confirm the Phase 2 efficacy signal and characterize the safety profile in larger populations. We’re monitoring the trial readouts closely.
Can I get retatrutide somewhere now?
Not through legitimate medical channels in the United States. Some compounding pharmacies and online sellers offer “research peptides” labeled as retatrutide, but these aren’t sourced through the FDA-approved supply chain. The quality, purity, and dosing accuracy of research-grade peptides varies dramatically, and using them carries real safety risks. We don’t prescribe these and don’t recommend obtaining them elsewhere.
How much better is retatrutide than tirzepatide?
Based on Phase 2 data, retatrutide produced mean weight loss of 24.2% at 48 weeks at the highest dose, compared to about 21-22% for tirzepatide over similar timeframes in separate trials. Note these aren’t head-to-head trials — no direct comparison has been conducted yet. The difference is meaningful but modest. For most patients, tirzepatide today is functionally close enough to retatrutide that waiting isn’t worth the delay.
Should I wait for retatrutide instead of starting tirzepatide?
For most patients, no. The 1-3 year delay until retatrutide is potentially available is a meaningful loss of weight loss progress, metabolic improvement, and health benefit. Tirzepatide today is the strongest FDA-approved option and produces results most patients describe as life-changing. If retatrutide becomes available during your treatment course, transitioning is a reasonable conversation at that point. Waiting now for an uncertain future approval isn’t usually the right move.
What’s the cost difference likely to be?
Retatrutide pricing isn’t yet established. Based on tirzepatide and semaglutide pricing patterns, we’d expect retatrutide to be in a similar range — likely $800 to $1300 per month at full retail without insurance, with substantial variation based on insurance coverage, manufacturer programs, and compounded alternatives. Cost will be a factor in the eventual prescribing decision for many patients.
What about long-term safety data?
This is the part of the FDA approval process that hasn’t been completed yet. Phase 2 data showed the safety profile in line with other GLP-1-class medications — primarily GI side effects, with the dose-dependent increases in heart rate that are characteristic of this drug class. Phase 3 trials will characterize safety in much larger populations over longer durations, and the FDA review will determine whether the risk-benefit profile supports approval. This is part of why we wait for legitimate approval rather than prescribing based on Phase 2 data alone.
Don’t wait for tomorrow. Start today.
The strongest FDA-approved weight loss medication is available now. Book a 45-minute consultation with one of our Houston physicians and start your metabolic health program today — with the option to transition to retatrutide if and when it’s approved.